Compare EQPT & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQPT | BLTE |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 8206 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.2B |
| IPO Year | N/A | 2021 |
| Metric | EQPT | BLTE |
|---|---|---|
| Price | $19.97 | $139.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $38.88 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 2.4M | 204.1K |
| Earning Date | 03-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.53 | N/A |
| Revenue Next Year | $23.15 | $492.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.95 | $56.68 |
| 52 Week High | $35.50 | $200.00 |
| Indicator | EQPT | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 42.21 |
| Support Level | $18.94 | $103.94 |
| Resistance Level | $26.57 | $157.99 |
| Average True Range (ATR) | 1.48 | 9.31 |
| MACD | -0.19 | 0.39 |
| Stochastic Oscillator | 31.46 | 41.30 |
EquipmentShare.com Inc is a vertically integrated platform that combines proprietary technology, a connected equipment fleet, and a nationwide footprint to serve the construction industry. The company operates its business through the following reportable segments: Equipment Rental and Services Operations, comprised of recurring activity performed at full-service branch locations, such as equipment rentals and related services, and sales of parts, supplies, and maintenance services to construction contractors and others. Equipment Sales, sales of new or used equipment made at any of the branch locations and dealership sites, including equipment sales to participants in the OWN Program.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.